A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

NCT07407348 · Recruiting

Last updated 2026-05-28

This study compares how two different versions of the drug survodutide are absorbed by the body in adults who are overweight or have obesity.

Status Recruiting Currently enrolling participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 80 people Planned (estimated).

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2026-02 · est. completion 2027-03

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT07407348 ↗

Description as written by the study sponsor.

The primary objective of this trial is to assess bioequivalence of two formulations of survodutide (formulation A and formulation B6) after multiple-dose treatment in male and female trial participants living with overweight or obesity.

Treatments tested

Formulation A Combination Product

Formulation A of survodutide
Formulation B6 Combination Product

Formulation B6 of survodutide

Main thing measured	Area under the concentration-time curve of survodutide in plasma at steady state over a uniform dosing interval tau (AUC tau,ss)
Sponsor	Boehringer Ingelheim
Conditions studied	Healthy, Obesity, Overweight
GLP-1 drugs	survodutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07407348 ↗